243 related articles for article (PubMed ID: 30340248)
1. Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.
Rowland A; Ruanglertboon W; van Dyk M; Wijayakumara D; Wood LS; Meech R; Mackenzie PI; Rodrigues AD; Marshall JC; Sorich MJ
Br J Clin Pharmacol; 2019 Jan; 85(1):216-226. PubMed ID: 30340248
[TBL] [Abstract][Full Text] [Related]
2. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Knights KM; Rowland A; Miners JO
Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
[TBL] [Abstract][Full Text] [Related]
3. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
4. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
Chan TS; Scaringella YS; Raymond K; Taub ME
Drug Metab Dispos; 2020 Aug; 48(8):690-697. PubMed ID: 32503882
[TBL] [Abstract][Full Text] [Related]
7. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Kong TY; Cheong JC; Kim HS; In MK; Lee HS
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287454
[TBL] [Abstract][Full Text] [Related]
8. Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism.
Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):751-767. PubMed ID: 29876844
[TBL] [Abstract][Full Text] [Related]
9. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
11. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
12. Human hepatocarcinoma functional liver cell-4 cell line exhibits high expression of drug-metabolizing enzymes in three-dimensional culture.
Kato R; Shigemoto K; Akiyama H; Ieda A; Ijiri Y; Hayashi T
Biol Pharm Bull; 2014; 37(11):1782-7. PubMed ID: 25366484
[TBL] [Abstract][Full Text] [Related]
13. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
[TBL] [Abstract][Full Text] [Related]
14. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Huwyler J; Wright MB; Gutmann H; Drewe J
Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
[TBL] [Abstract][Full Text] [Related]
15. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.
van Dyk M; Marshall JC; Sorich MJ; Wood LS; Rowland A
Eur J Clin Pharmacol; 2018 Jul; 74(7):913-920. PubMed ID: 29572563
[TBL] [Abstract][Full Text] [Related]
16. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Rodrigues AD; Wood LS; Vourvahis M; Rowland A
Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
[TBL] [Abstract][Full Text] [Related]
17. Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
van Dyk M; Miners JO; Marshall JC; Wood LS; Hopkins A; Sorich MJ; Rowland A
Eur J Clin Pharmacol; 2019 Sep; 75(9):1211-1218. PubMed ID: 31123759
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
[TBL] [Abstract][Full Text] [Related]
19. Significantly decreased and more variable expression of major CYPs and UGTs in liver microsomes prepared from HBV-positive human hepatocellular carcinoma and matched pericarcinomatous tissues determined using an isotope label-free UPLC-MS/MS method.
Yan T; Gao S; Peng X; Shi J; Xie C; Li Q; Lu L; Wang Y; Zhou F; Liu Z; Hu M
Pharm Res; 2015 Mar; 32(3):1141-57. PubMed ID: 25288013
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Kinetic Characterization of Axitinib Metabolism.
Zientek MA; Goosen TC; Tseng E; Lin J; Bauman JN; Walker GS; Kang P; Jiang Y; Freiwald S; Neul D; Smith BJ
Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]